ALKEM Stock View

Alkem Laboratories Ltd
stock-view-header

₹ 3,395.7

icon 27.35 | 0.81
Market Cap ₹( Cr.)
406,006.90
Proj. P/E (x)
25.35
Proj. P/BV (x)
3.90
Proj. ROE (%)
15.96
Proj EV / EBITDA (x)
--
Proj. Revenue ( Cr.)
130,763.57

Stock View

HOLD

Last Updated On.
04-Jun-2023
 

The average score for Alkem Laboratories Ltd stands at 5 against 6, three months back.

Alkem Laboratories Limited is a pharmaceutical company. The Company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The Company operates through pharmaceuticals segment. The Company produces generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals, which it markets in India and approximately 50 countries internationally. The Company offers its products across various therapeutic areas, such as anti-infective, dermatology, diabetology, cardiology, gastroenterology, osteoporosis, Rheumatology, central nervous system (CNS), oncology, urology and gynecology. The Company offers its products under various brands, including Clavam, Pan, Pan-D, Taxim-O, A To Z NS, Xone, Gemcal, Taxim, Sumo, Maxvoid Plus, Tamsukem Plus and Neurokem NT. The Company has approximately 20 manufacturing facilities, of which 18 manufacturing facilities are located in India and two in the United States.

Disclaimer : All estimates (1 year forward) are based on Consensus View provided by Refinitiv.


Technical Data

50 DMA(₹)
3,370.46
100 DMA(₹)
3,249.55
200 DMA(₹)
3,181.63
52 Weeks Range
2,835.05     3,624.80